Purpose: To evaluate the toxic retinal effects of intravitreal bevacizumab used for the treatment of exudative age-related macular degeneration (AMD) using Ganzfeld Electroretinography (G-ERG) Methods: In this prospective comparative interventional study, 23 patients with active choroidal neovascularization (CNV) associated with AMD were enrolled. Patients were received intravitreal injections ...

OBJECTIVE To determine if prophylactic use of intraocular pressure (IOP)-lowering medication is effective in reducing the IOP spikes after intravitreal injections of pegaptanib, bevacizumab, and ranibizumab. METHODS Seventy-one patients with exudative age-related macular degeneration received intravitreal injections of 1 of 3 anti-vascular endothelial growth factor medications: 30 patients re...

BACKGROUND The number of patients treated with intravitreal injections has increased significantly over the past few years, mainly following the introduction of anti-vascular endothelial growth factor antibody intraocular drugs. Bevacizumab is mostly used in this group of medications. OBJECTIVES To describe persistent elevation of intraocular pressure (IOP) following intravitreal injection of...

AIM To investigate whether single-dose intravitreal injections of bevacizumab and ranibizumab transfer into milk. METHODS This study included lactating 12 sheep and a single 3-month old suckling lamb of each sheep. Two groups consisting of 6 sheep and their lambs were constituted; the ranibizumab group and the bevacizumab group before the administration of intravitreal injections, blood and m...

PURPOSE To investigate the short-term effects of panretinal photocoagulation (PRP) combined with an intravitreal injection of Avastin(bevacizumab) as an adjuvant to high-risk proliferative diabetic retinopathy (PDR). METHODS The data was collected retrospectively from the eyes of high-risk PDR patients, which were divided into two groups. One eye was treated with only PRP (PRP only group) and...

PURPOSE To assess the short-term safety and efficacy of an intravitreal injection of bevacizumab in a patient with neovascular glaucoma. CASE REPORT Intravitreal bevacizumab injection was given in a patient with neovascular glaucoma and the changes in the visual acuity, intraocular pressure (lOP), iris neovascularisation were noted before injection and after one day, one week, three weeks and...

PURPOSE We report a case of infectious endophthalmitis that developed after the third intravitreal injection of bevacizumab. The endophthalmitis was caused by Staphylococcus epidermidis. METHODS Observational case series. RESULTS This was a case of a 77-year-old man who had received three intravitreal injections of bevacizumab and developed infectious endophthalmitis. Polymerase chain react...

PURPOSE To evaluate the role of intravitreal triamcinolone acetonide in patients who developed severe, visually compromising radiation maculopathy or progressed despite anti-angiogenic treatments. METHODS An Institutional Review Board approved, consecutive, retrospective study from 2006 to 2009 of patients who developed severe, visually compromising radiation retinopathy manifesting as macula...

Purpose To determine the intravitreal pharmacokinetic properties and to study the systemic biodistribution characteristics of I-124-labeled bevacizumab, ranibizumab, and aflibercept with positron emission tomography-computed tomography (PET/CT) imaging in a nonhuman primate model. Methods Three groups with four owl monkeys per group underwent intravitreal injection with 1.25 mg/0.05 mL I-124 ...